
- <Centre d'Information et de documentation du CRA Rhône-Alpes
- CRA
- Informations pratiques
-
Adresse
Centre d'information et de documentation
Horaires
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexLundi au Vendredi
Contact
9h00-12h00 13h30-16h00Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Adresse
Détail de l'auteur
Auteur Craig ERICKSON |
Documents disponibles écrits par cet auteur (22)



Adrienne Fitzer, Peter Sturmey (eds): Language and Autism: Applied Behavior Analysis, Evidence, and Practice / Kelly BLANKENSHIP in Journal of Autism and Developmental Disorders, 40-5 (May 2010)
![]()
[article]
Titre : Adrienne Fitzer, Peter Sturmey (eds): Language and Autism: Applied Behavior Analysis, Evidence, and Practice : PRO-ED, Inc., Austin, Texas, 2009, 342pp., $50.95 (paper) Type de document : Texte imprimé et/ou numérique Auteurs : Kelly BLANKENSHIP, Auteur ; Craig ERICKSON, Auteur Année de publication : 2010 Article en page(s) : p.647-648 Langues : Anglais (eng) Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1007/s10803-009-0833-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=101
in Journal of Autism and Developmental Disorders > 40-5 (May 2010) . - p.647-648[article] Adrienne Fitzer, Peter Sturmey (eds): Language and Autism: Applied Behavior Analysis, Evidence, and Practice : PRO-ED, Inc., Austin, Texas, 2009, 342pp., $50.95 (paper) [Texte imprimé et/ou numérique] / Kelly BLANKENSHIP, Auteur ; Craig ERICKSON, Auteur . - 2010 . - p.647-648.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 40-5 (May 2010) . - p.647-648
Index. décimale : PER Périodiques En ligne : http://dx.doi.org/10.1007/s10803-009-0833-1 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=101 Brief Report: Acamprosate in Fragile X Syndrome / Craig ERICKSON in Journal of Autism and Developmental Disorders, 40-11 (November 2010)
![]()
[article]
Titre : Brief Report: Acamprosate in Fragile X Syndrome Type de document : Texte imprimé et/ou numérique Auteurs : Craig ERICKSON, Auteur ; Jennifer E. MULLETT, Auteur ; Christopher J. MCDOUGLE, Auteur Année de publication : 2010 Article en page(s) : p.1412-1416 Langues : Anglais (eng) Mots-clés : Acamprosate Fragile X syndrome mGluR5 Language Irritability Index. décimale : PER Périodiques Résumé : Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism. En ligne : http://dx.doi.org/10.1007/s10803-010-0988-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=114
in Journal of Autism and Developmental Disorders > 40-11 (November 2010) . - p.1412-1416[article] Brief Report: Acamprosate in Fragile X Syndrome [Texte imprimé et/ou numérique] / Craig ERICKSON, Auteur ; Jennifer E. MULLETT, Auteur ; Christopher J. MCDOUGLE, Auteur . - 2010 . - p.1412-1416.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 40-11 (November 2010) . - p.1412-1416
Mots-clés : Acamprosate Fragile X syndrome mGluR5 Language Irritability Index. décimale : PER Périodiques Résumé : Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). We report on the first trial of acamprosate, a drug with putative mGluR5 antagonism, in three adults with FXS and autism. Medical records describing open-label treatment with acamprosate in 3 patients with FXS and a comorbid diagnosis of autistic disorder were reviewed. In all three patients, acamprosate was associated with improved linguistic communication. Three patients received acamprosate over a mean 21.3 weeks of treatment. All patients showed global clinical benefit as rated with the Clinical Global Impressions-Improvement scale. Marked communication improvement was unexpected and has potential implications for the treatment of FXS, as well as idiopathic autism. En ligne : http://dx.doi.org/10.1007/s10803-010-0988-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=114 Brief Report: Diminished Gaze Preference for Dynamic Social Interaction Scenes in Youth with Autism Spectrum Disorders / Rebecca C. SHAFFER in Journal of Autism and Developmental Disorders, 47-2 (February 2017)
![]()
[article]
Titre : Brief Report: Diminished Gaze Preference for Dynamic Social Interaction Scenes in Youth with Autism Spectrum Disorders Type de document : Texte imprimé et/ou numérique Auteurs : Rebecca C. SHAFFER, Auteur ; Ernest V. PEDAPATI, Auteur ; Frederick SHIC, Auteur ; Kristina GAIETTO, Auteur ; Katherine BOWERS, Auteur ; Logan K. WINK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.506-513 Langues : Anglais (eng) Mots-clés : Eye tracking Autism spectrum disorder Social interest Social impairment ASD Index. décimale : PER Périodiques Résumé : In this study, we present an eye-tracking paradigm, adapted from previous work with toddlers, for assessing social-interaction looking preferences in youth ages 5–17 with ASD and typically-developing controls (TDC). Videos of children playing together (Social Scenes, SS) were presented side-by-side with animated geometric shapes (GS). Participants with ASD demonstrated reduced SS preferences compared to TDC, results also represented continuously by associations between higher SS preferences and fewer social difficulties across the combined sample. Exploratory analyses identified associations between increased SS preferences and higher Vineland Daily Living Skills in ASD and suggested SS preferences in TDC females might drive ASD versus TDC between-group differences. These findings describe potentially sex-linked couplings between preferences for social information and social functioning in school-aged children. En ligne : http://dx.doi.org/10.1007/s10803-016-2975-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=303
in Journal of Autism and Developmental Disorders > 47-2 (February 2017) . - p.506-513[article] Brief Report: Diminished Gaze Preference for Dynamic Social Interaction Scenes in Youth with Autism Spectrum Disorders [Texte imprimé et/ou numérique] / Rebecca C. SHAFFER, Auteur ; Ernest V. PEDAPATI, Auteur ; Frederick SHIC, Auteur ; Kristina GAIETTO, Auteur ; Katherine BOWERS, Auteur ; Logan K. WINK, Auteur ; Craig ERICKSON, Auteur . - p.506-513.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-2 (February 2017) . - p.506-513
Mots-clés : Eye tracking Autism spectrum disorder Social interest Social impairment ASD Index. décimale : PER Périodiques Résumé : In this study, we present an eye-tracking paradigm, adapted from previous work with toddlers, for assessing social-interaction looking preferences in youth ages 5–17 with ASD and typically-developing controls (TDC). Videos of children playing together (Social Scenes, SS) were presented side-by-side with animated geometric shapes (GS). Participants with ASD demonstrated reduced SS preferences compared to TDC, results also represented continuously by associations between higher SS preferences and fewer social difficulties across the combined sample. Exploratory analyses identified associations between increased SS preferences and higher Vineland Daily Living Skills in ASD and suggested SS preferences in TDC females might drive ASD versus TDC between-group differences. These findings describe potentially sex-linked couplings between preferences for social information and social functioning in school-aged children. En ligne : http://dx.doi.org/10.1007/s10803-016-2975-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=303 Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study / Logan K. WINK in Journal of Autism and Developmental Disorders, 51-4 (April 2021)
![]()
[article]
Titre : Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study Type de document : Texte imprimé et/ou numérique Auteurs : Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.1392-1399 Langues : Anglais (eng) Mots-clés : Autism Clinical trial Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N?=?21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445
in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399[article] Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder-Initial Results of a Randomized, Controlled, Crossover, Pilot Study [Texte imprimé et/ou numérique] / Logan K. WINK, Auteur ; Debra L. REISINGER, Auteur ; Paul HORN, Auteur ; Rebecca C. SHAFFER, Auteur ; Kaela O'BRIEN, Auteur ; Lauren M. SCHMITT, Auteur ; Kelli R. DOMINICK, Auteur ; Ernest V. PEDAPATI, Auteur ; Craig ERICKSON, Auteur . - p.1392-1399.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 51-4 (April 2021) . - p.1392-1399
Mots-clés : Autism Clinical trial Ketamine Index. décimale : PER Périodiques Résumé : Dysregulation of glutamate neurotransmission plays a critical role in autism spectrum disorder (ASD) pathophysiology and is a primary target for core deficit research treatment trials. The mechanism of action of ketamine has striking overlap with the theory of ASD as a disorder of synaptic communication and neuronal networks. This two-dose, double-blind, placebo controlled, cross-over pilot trial of intranasal (IN) ketamine targeting core social impairment included individuals with ASD (N?=?21) between 14 and 29 years. Participants were randomized to received two doses of IN ketamine (30 and 50 mg) and two doses of matching placebo. No significant impact was noted on the Aberrant Behavior Checklist Social Withdraw subscale. The IN ketamine was well tolerated, with only transient mild adverse effects. En ligne : http://dx.doi.org/10.1007/s10803-020-04542-z Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=445 Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder / Logan K. WINK in Journal of Autism and Developmental Disorders, 47-7 (July 2017)
![]()
[article]
Titre : Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur Article en page(s) : p.2290-2294 Langues : Anglais (eng) Mots-clés : Autism Autism spectrum disorder Metformin Antipsychotic Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314
in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294[article] Brief Report: Metformin for Antipsychotic-Induced Weight Gain in Youth with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Logan K. WINK, Auteur ; Ryan E. ADAMS, Auteur ; Ernest V. PEDAPATI, Auteur ; Kelli C. DOMINICK, Auteur ; Emma FOX, Auteur ; Catherine BUCK, Auteur ; Craig ERICKSON, Auteur . - p.2290-2294.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 47-7 (July 2017) . - p.2290-2294
Mots-clés : Autism Autism spectrum disorder Metformin Antipsychotic Weight gain Index. décimale : PER Périodiques Résumé : Antipsychotic treatment in youth with autism spectrum disorder (ASD) is becoming increasingly common, placing individuals at risk for antipsychotic-induced weight gain and associated complications. Metformin hydrochloride, a biguanide medication FDA-approved for treatment of type-2 diabetes in youth, may hold promise for treatment of antipsychotic-induced weight gain in youth with ASD. In this report we assess the long-term impact of metformin on antipsychotic-associated weight gain in a naturalistic sample of 53 youth with ASD. Results indicate that treatment with metformin stabilized BMI z-score over a nearly 2 year mean treatment period. Further work is indicated to determine the safety and efficacy of metformin treatment in youth with ASD, as well as predictors of response as a treatment for antipsychotic-induced weight gain. En ligne : https://doi.org/10.1007/s10803-017-3132-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=314 Brief Report: Pilot Single-Blind Placebo Lead-In Study of Acamprosate in Youth with Autistic Disorder / Craig ERICKSON in Journal of Autism and Developmental Disorders, 44-4 (April 2014)
![]()
PermalinkBrief Report: Telehealth Satisfaction Among Caregivers of Pediatric and Adult Psychology and Psychiatry Patients with Intellectual and Developmental Disability in the Wake of Covid-19 / Victoria ROSEN in Journal of Autism and Developmental Disorders, 52-12 (December 2022)
![]()
PermalinkCase Report: 16-Year-Old Male with Autistic Disorder with Preoccupation with Female Feet / Maureen C. EARLY in Journal of Autism and Developmental Disorders, 42-6 (June 2012)
![]()
PermalinkCase Report: Is Catatonia a Clinical Feature of the Natural Progression of NLGN2-Related Neurodevelopmental Disorder? / Amelle SHILLINGTON in Journal of Autism and Developmental Disorders, 51-1 (January 2021)
![]()
PermalinkDrug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: A chart review study / Benjamin A. ADLER in Autism, 19-1 (January 2015)
![]()
PermalinkPermalinkGastrointestinal Symptoms in a Sample of Children with Pervasive Developmental Disorders / Roumen N. NIKOLOV in Journal of Autism and Developmental Disorders, 39-3 (March 2009)
![]()
PermalinkOpen-Label Memantine in Fragile X Syndrome / Craig ERICKSON in Journal of Autism and Developmental Disorders, 39-12 (December 2009)
![]()
PermalinkPediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome / Sarah E. FITZPATRICK in Journal of Autism and Developmental Disorders, 50-3 (March 2020)
![]()
PermalinkPhenotypic differences in individuals with autism spectrum disorder born preterm and at term gestation / Katherine BOWERS in Autism, 19-6 (August 2015)
![]()
Permalink